Steward Partners Investment Advisory’s Astria Therapeutics ATXS Stock Holding History

Steward Partners Investment Advisory’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3	Closed	-$39	–	4427
2025 Q4	$39	Hold	3	–	–	﹤0.01%	4260
2025 Q3	$22	Buy	+3	New	+$20	﹤0.01%	4227

Steward Partners Investment Advisory's ATXS Position: Q1 2026 in Review

Steward Partners Investment Advisory sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 3 shares — an estimated $39 sold.

Steward Partners Investment Advisory first reported a position in ATXS in Q3 2025 and held it in 2 quarters. The position peaked at $39 in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Steward Partners Investment Advisory reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Steward Partners Investment Advisory sold 3 Astria Therapeutics shares in Q1 2026, an estimated $39.
Steward Partners Investment Advisory first reported a position in Astria Therapeutics in Q3 2025 and held it in 2 quarters.
Steward Partners Investment Advisory's Astria Therapeutics position peaked at $39 in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.